

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. Canceled

12. (Currently Amended) A method for stimulating an immune response in a patient, comprising administering to the patient ~~a composition of claim 11~~ at least an immunogenic fragment of the polypeptide of SEQ ID NO: 525, wherein said fragment contains an amino acid sequence capable of stimulating a human T-cell response.

13. (Currently Amended) A method for the treatment of a cancer in a patient, comprising administering to the patient ~~a composition of claim 11~~ at least an immunogenic fragment of the polypeptide of SEQ ID NO: 525, wherein said fragment contains an amino acid sequence capable of stimulating a human T-cell response.

14-16. Canceled

17. (Currently Amended) A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least ~~one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen-presenting cells that express a polypeptide of claim 2, such that T cells proliferate~~ an immunogenic fragment of the polypeptide of SEQ ID NO: 525, wherein said fragment contains an amino acid sequence capable of stimulating a human T-cell response, under conditions such that T cells proliferate;

(b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

18. (New) A method for stimulating and/or expanding T cells specific for a prostate tumor protein, comprising contacting T cells with at least an immunogenic fragment of the polypeptide of SEQ ID NO: 525, wherein said fragment contains an amino acid sequence

capable of stimulating a human T-cell response, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

19. (New) The method according to any one of claims 12, 13, 17 and 18, wherein said immunogenic fragment that contains an amino acid sequence capable of stimulating a human T-cell response is selected from the group consisting of:

- (a) amino acid residues 110-124 of SEQ ID NO: 525;
- (b) amino acid residues 125-139 of SEQ ID NO: 525;
- (c) amino acid residues 135-149 of SEQ ID NO: 525;
- (d) amino acid residues 155-170 of SEQ ID NO: 525; and
- (e) amino acid residues 160-174 of SEQ ID NO: 525.